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In the present review, microvascular remodelling refers to alterations in the structure of resistance
vessels contributing to elevated systemic vascular resistance in hypertension. We start with some his-
torical aspects, underscoring the importance of Folkow’s contribution made half a century ago. We
then move to some basic concepts on the biomechanics of blood vessels, and explicit the deﬁnitions pro-
posed by Mulvany for speciﬁc forms of remodelling, especially inward eutrophic and inward hyper-
trophic. The available evidence for the existence of remodelled resistance vessels in hypertension
comes next, with relatively more weight given to human, in comparison with animal data. Mechanisms
are discussed. The impact of antihypertensive drug treatment on remodelling is described, again with
emphasis on human data. Some details are given on the three studies to date which point to remodelling
of subcutaneous resistance arteries as an independent predictor of cardiovascular risk in hypertensive
patients. We terminate by considering the potential role of remodelling in the pathogenesis of end-
organ damage and in the perpetuation of hypertension.
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Hypertension elicits two different kinds of diffuse structural
changes in the systemic microcirculation. One, termed rare-
faction, consists in an abnormally low spatial density of
arterioles, capillaries, and possibly venules. The other con-
cerns structural modiﬁcations of resistance small arteries
and arterioles, which lead to a reduction in lumen diameter
and are grouped under the generic name of remodelling. We
have recently reviewed rarefaction in detail.1 The focus of
the present paper is on remodelling which probably accounts
for the major part of long-term elevation of systemic vascu-
lar resistance (SVR) in hypertensive patients.
1. Historical note
The ﬁrst intellectual association of hypertensive disease
with diffuse abnormalities of the microcirculation may be
traced back to Richard Bright, a father of nephrology, who
in the third decade of the 19th century brilliantly described
the natural course of what became to be known as Bright’s
disease, in fact a heterogeneous class of chronic nephropa-
thies. Bright noted the presence of a hard pulse2 and the fre-
quent autopsy ﬁnding of left ventricular hypertrophy
unexplained by gross cardiac or aortic defect.3 In the
excerpt shown in Figure 1, one may follow the line of
thought which led Bright to hypothesize a diffuse
microcirculatory derangement. In 1869, George Johnson
provided the ﬁrst histological evidence of wall thickening
in small arteries of various organs obtained at the autopsy
of patients who suffered from Bright’s disease (Figure 2).4
Johnson was well aware that blood pressure in Bright’s
disease was abnormally high. A decade later, the concept
that heightened blood pressure may precede and be a
cause rather than a consequence of altered microvascular
architecture was introduced by Ewald,5,6 who was also the
ﬁrst to propose the ratio of wall thickness to lumen diameter
for the assessment of abnormal microvessel structure.7 Of
note, it is only later, i.e. in the ﬁrst two decades of the
20th century, that essential hypertension became estab-
lished as a nosographic entity.6 The ﬁrst quantitative study
of arteriolar structure in hypertensive disease, using
modern histological methods as well as a relatively crude
form of morphometry, was published in 1929 (Figure 3).8
In the ensuing decades, the discovery of the Goldblatt’s
models and the renin–angiotensin system were important
factors explaining that the focus of hypertension research
shifted towards functional and away from structural
aspects of resistance vessel abnormalities.6,9 The pioneering
work of Bjo¨rn Folkow started the pendulum moving in a
different direction, demonstrating that hypertension was
associated with abnormally high resistance to blood ﬂow,
even in maximally dilated vascular beds, a strong evidence
for the haemodynamic importance of altered microvascular
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hypertensive circulation.10 It took however a good
additional 20 years before systematic interest progressively
developed in other groups of investigators for the vascular
structural factor in hypertension.11–14
2. Deﬁnitions and basic concepts
2.1 Resistance vessels
Resistance vessels are those which concentrate the major
part of the pressure drop that must occur between large
conduit arteries and capillaries. It has been underscored
that their exact anatomical location is hard to deﬁne pre-
cisely,15 but they are commonly believed to encompass
small arteries and arterioles, with diameters ranging from
300 to 15 mm.16 Resistance vessels are characterized by
the presence of myogenic tone, i.e. their intrinsic ability
to contract in response to a sudden increase of transmural
pressure.1 Important to note, myogenic tone becomes
more and more vigorous as vessel size decreases.17
2.2 Structural design and adaptability of blood
vessels
A fundamental tool to understand the varying structure of
different blood vessels in different conditions is the
Laplace law, which for any tubular element with cylindrical
geometry relates intramural stress (s), wall thickness (W ),
Figure 2 First description of wall thickening of small arteries in hypertension. These drawings are taken from the 1868 paper by George Johnson.4 They rep-
resent microscopic views of small skin arteries, one normal (upper drawing) and one from a patient who at autopsy presented with an abnormal kidney and left
ventricular hypertrophy (lower drawing). Reproduced with permission by RSM Publishing.
Figure 1 Title and excerpt from Richard Bright’s original report The black
bar in the margin draws attention to the mention made of the microcircula-
tion. The excerpt straddles pages 396 and 397 in the original publication.3
Reproduced with permission by ISS Enquiry.
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lumen radius (r), and transmural pressure (P, the difference
between luminal and extraluminal pressures) according to
the equation:
s ¼ Pr
W
which may be rewritten in terms of theW to lumen diameter
(D) ratio as
s ¼ 0:5 PðW=DÞ
Laplace law dictates vascular structure so as to maintain s
within a relatively tight domain across vessel type, species,
and conditions. Within an individual, there is high plasticity
of vascular structure, which continuously adapts to accom-
modate changing conditions of mechanical load, as in fact
do other organs such as skeletal muscle and bone. This is
well exempliﬁed by the thickness difference between sys-
temic and pulmonary conduit arteries, which is non-existent
in the foetus, and develops only after closure of the ductus
arteriosus.18 Evidence of plasticity beyond the developmen-
tal stage is given by the wall thickening of venous grafts
exposed to systemic pressure.19
2.3 The Folkow hypothesis
In his pioneering work already mentioned, Folkow used
plethysmography to measure forearm blood ﬂow under
conditions of maximal vasodilation, and from that he
derived the minimal resistance (Rmin) of this vascular
bed.9,10 Forearm Rmin was found abnormally high in hyper-
tensive subjects, an observation which, along with other
data gathered in these experiments, was taken as evidence
that a structural factor contributed to elevate systemic vas-
cular resistance in these patients. In a bold intellectual
move, Folkow proposed that structural alterations could
lead to increased resistance even at normal levels of vascu-
lar tone. In simpliﬁed form, reasoning was as follows. First,
even minor reductions in lumen diameter (D) may have
major effects on vessel resistance, because the latter is
inversely proportional on the fourth power of the radius
(Poiseuille law). Second, hypertensive structural alterations
of resistance arteries consist in wall thickening and
increased W/D ratio, with wall elements encroaching on
the lumen, hence structurally reducing D, and increasing
Rmin. Third, in conditions of increased W/D the same level
of vascular tone, causing the same shortening of SMCs,
leads for simple geometrical reasons to a greater reduction
of D. In other words, the structurally modiﬁed resistance
arteries in hypertension function as ampliﬁers of vascular
tone, which thus needs not be augmented for vascular
resistance and blood pressure to be higher than in the
normotensive state.
Folkow’s view permeates all contemporary thinking on
the pathogenesis of elevated blood pressure in chronic
hypertension. It is now widely accepted that, important as
its is, vascular tone is only a short-term modulator, while
structural adaptation of resistance vessels is an obligatory
Figure 3 First quantitative evidence of abnormal resistance vessel structure in hypertension.8 Data from biopsies of the pectoral muscle carried out in 50 norm-
tensive subjects (upper curve), 11 patients with “benign” hypertension (middle curve), and 41 patients with malignant hypertension (lower curve). The mean
ratio of wall thickness to lumen diameter was measured in arterioles and small arteries (25–100 mm). To help legibility, the original ﬁgure has been overlaid with
repeats of some labels. Reproduced with permission from the American Medical Association & 1929. All Rights reserved.
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requirement for elevated blood pressure to be maintained
for any prolonged period.20–23
2.4 Further concepts
Folkow’s hypothesis has both the advantages and disadvan-
tages of simplicity. Notably, it focuses on s as the single
determinant of vascular structural reshaping, while the
shear stress (t) generated on endothelial lining by ﬂowing
blood is now of recognized importance. A durable increase
in s is counteracted by an augmented W/D ratio,9 but a
durable increase in t results in structural augmentation of
D (thus tending to reduce blood velocity).24 Adding to com-
plexity, s and t are highly interdependent. For example, the
higher D resulting from an increase in t tends to raise s by
virtue of the Laplace law. Pries et al.25 obtained extensive
geometrical and mechanical data in the relaxed mesenteric
vasculature of anesthetized rats. This enabled them to con-
struct a sophisticated mathematical model of this vascular
bed, which notably included the following: (i) several hun-
dreds of vessels, arteriolar, capillary, and venular, (ii) the
non-Newtonian nature of blood ﬂow in small vessels (D ,
300 mm);26 (iii) quantitative rules which applied uniformly
across all vessels in the network, everywhere relating s, t,
geometry, blood ﬂow, transmural pressure, and additional
factors such as metabolic demand.27 This model faithfully
reproduced the structural changes observed experimentally
in the mesenteric circulation of hypertensive rats.
2.5 Vascular remodelling
2.5.1 Nomenclature
In the historical work cited above, the increased W of hyper-
tensive resistance vessels was uniformly ascribed to a higher
volume of wall material per unit length of vessel [increased
wall cross-sectional area (CSA)], or ‘hypertrophy’. It was
assumed that smooth muscle cells in resistance vessels
behaved as did left ventricular myocytes in the face of the
increased pressure load, and that growth took place
mainly on the luminal side, leading to a structural reduction
of internal diameter (D). In 1966, Short28 carried out a
careful quantitative geometrical analysis of intestinal
small arteries and arterioles in patients with essential
hypertension. He observed that, although W of these
vessels was higher, and D smaller than in normotensive con-
trols, media CSA was the same in the two groups of subjects.
This ﬁnding was not compatible with a structural alteration
of hypertensive vessels due to growth alone. The term remo-
delling was ﬁrst applied to resistance vessels by Baumbach
and Heistad,29 based on observations made in pial arterioles
from stroke-prone spontaneously hypertensive rats
(SPSHRs), to indicate a structural rearrangement of existing
wall material around a smaller lumen.
Noting that the narrow deﬁnition adopted by Baumbach
and Heistad conﬂicted with other usages of the same term
(i.e. myocardial remodelling), Mulvany30 proposed that vas-
cular remodelling should encompass any change in D noted
in a fully relaxed vessel, not explained by a change in
transmural pressure or compliance, and therefore due to
structural factors. In addition, a two-way classiﬁcation
scheme was put forward (Figure 4). Remodelling could be
inward or outward, depending on whether D decreased or
increased, and hypertrophic, eutrophic, or hypotrophic if
respectively contributed to by net growth (increased CSA),
no net change in amount of tissue (constant CSA), or net
loss of tissue (decreased CSA). With that terminology, the
structural abnormalities noted by Short in intestinal
arterioles28 are of course described as inward eutrophic
remodelling. For elementary geometrical reasons, inward
eutrophic and hypertrophic remodelling are always associ-
ated with increased W and W/D ratio, the opposite being
true of outward eutrophic and hypotrophic remodelling30
(Figure 4).
The terminology just described has spurred some contro-
versy.31,32 Importantly, eutrophic remodelling should not
be construed as necessarily and exclusively implying
rearrangement of existing components.33 Mulvany’s32 termi-
nology may indeed pose problems if automatically equated
with distinct pathophysiological processes, but remains
useful as long as no implicit assumptions are being made
on underlying mechanisms.
2.5.2 Methodology
To be operational, the classiﬁcation shown in Figure 4
necessitates appropriate methods for the measurement of
resistance vessels dimensions. This problem is much harder
than would seem at ﬁrst sight.31
To meet the deﬁnition of remodelling given above, the
respective sizes of hypertensive and normotensive small
arteries and arterioles must be compared with the inﬂuence
of the following factors either removed or controlled for: (i)
vascular tone, (ii) transmural pressure, and (iii) vessel com-
pliance. Obviously, none of these requirements would be
met by geometrical measurements made on standard histo-
logical sections prepared without perfusion of the tissue
sample (e.g. shrinking artefacts).
One widely used approach, possible with small arteries
(100 and 300 mm), is to carry out geometrical measurements
on dissected segments put in standardized conditions in
vitro. The segments are mounted in an organ chamber
Figure 4 Subtypes of vascular remodelling. Each pair of concentric circles
represents a vessel in cross-sectional view. Depicted in the centre of the
ﬁgure is the reference state, with respect to which structural changes
occur. CSA wall (or media) cross-sectional area. D, lumen diameter. W, Wall
thickness. Modiﬁed from ref.30, with author’s permission.
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(myograph), fully relaxed by applying a vasodilator in
maximal concentration, and then distended in a standar-
dized fashion. There are two variants of this approach,
one using the wire myograph (the most ancient one),34
and the other the pressure myograph. In addition to standar-
dized geometry, both methods allow detailed measurements
of passive mechanical properties, thus making it possible to
distinguish alterations in geometry due to changes in wall
elasticity from those due to other causes (i.e. remodelling
stricto sensu). The disadvantages of myography are 2-fold.
The ﬁrst one has been called the sampling problem.33
Whether the arterial segments assessed with this approach
are representative of resistance vessels in the studied
organ (not to speak of the whole organism) is open to ques-
tion. More subtly, for meaningful comparison of hyperten-
sive and normotensive state, it is necessary that the
vascular tree be sampled at identical branching level in
both conditions, but veriﬁcation of this requirement is not
easy. The second disadvantage of myography resides in the
partly arbitrary choice of transmural pressure under which
geometry is measured. In particular, one may question the
appropriateness of setting this variable at the same level
for hypertensive and normotensive vessels, as most studies
reviewed below have done.
3. Morphologic evidence for remodelling of
small vessels in untreated hypertension
3.1 Animal data
A considerable amount of studies have investigated struc-
tural alterations of resistance arteries and arterioles in a
large variety of hypertensive models, mostly in the rat,
with relatively little work done in other species. The
majority of studies have used a popular model of genetically
determined hypertension, the SHR. A fundamental problem
with this model is the lack of rigorous normotensive con-
trols, since the Wistar-Kyoto rat (WKY) used to that effect
differs from the SHR by many genetic markers, only a min-
ority of which are linked to hypertension.35 To mitigate
this concern, alterations of microcirculatory structure
broadly similar to those demonstrated in SHRs have been
found in several other models for which fully adequate con-
trols exist, such as transgenic rats expressing the mouse
Ren-2 renin gene (mRen-2),36–39 or rats made hypertensive
by surgical (Goldblatt)40–42 or pharmacological means.43–45
In a variety of hypertensive animal models (both genetic
and secondary), media hypertrophy seems progressively
less important as vessel size decreases, whereas eutrophic
remodelling is most readily observed in the more distal
part of arterial microcirculation.36,42,46–48 For example,
Miller et al.46 have examined perfusion-ﬁxed submucosal
intestinal 1A (largest) to 4A (smallest) arterioles from
SHRs. While the W/D ratio was abnormally high in hyperten-
sive vessels of all sizes, only at the 1A level was media CSA
increased in comparison with WKY controls. In mRen-2 trans-
genic rats,36 impressive media hypertrophy was found in the
large main mesenteric arteries,37 while inward eutrophic
remodelling predominated further downstream in this vas-
cular bed.36 Similar observations of large vs. small mesen-
teric47 and kidney48 arteries are available in SHRs. Below,
we shall provide a simple mechanical explanation to this
pattern of proximal hypertrophic, progressively blending
into distal eutrophic (at times hypotrophic) remodelling.
The deﬁnition of remodelling includes the requirement
that changes in D and W/D at comparable distending
pressure should not be due to altered wall elasticity. In
the paper that originated the concept of eutrophic remodel-
ling, as already mentioned, pial arterioles of SPSHRs had
reduced D increased W/L and increased distensibility in
comparison with those of normotensive controls, thus
ruling out stiffening of vessel wall as a cause of the observed
morphological alterations.29 Similar conclusions were
reached in several,49,50 but not all studies.38,51
Whether an abnormally high media CSA reﬂects cellular
hypertrophy or hyperplasia has received variable answers.
In general, there has been evidence of smooth muscle
cells hyperplasia (with or without hypertrophy) in SHRs43,47
and SPSHRs,52 i.e. genetic models, whereas SMC hypertro-
phy without hyperplasia was found in models of secondary
hypertension.41,43 This difference between models may be
related to the particular ability of SHR’s ﬁbroblasts and
SMCs to multiply rapidly under the inﬂuence of growth
factors.33 However, this trait is of doubtful relevance to
the pathogeny of hypertension, because it does not cosegre-
gate with blood pressure in SHR/WKY F2 hybrids.33
3.2 Clinical data
The most feasible possibility for quantitative structural
studies of resistance vessels in humans relies on the examin-
ation of small muscular (presumably resistance) arteries
from biopsies of subcutaneous gluteal fat carried out
under local anaesthesia. Small arteries can also be obtained
from omental fat excised at the time of abdominal
surgery.14,53,54 The dissected vessels are mounted in a wire
or pressure myograph and characterized with the aforemen-
tioned methodology. Due to the invasive character of these
procedures, most relevant studies are of modest size, typi-
cally involving between 10 and 20 subjects per group (with
a few notable exceptions55–57). Furthermore untreated
hypertensives are often patients in whom medication was
withdrawn for a few weeks, rather than being newly
diagnosed. With these caveat in mind, one may read in
Figure 5 summary of the available information on the com-
parative structure of small subcutaneous12,14,51,53,55,56,58–71
or omental14,53 arteries from untreated hypertensive and
normotensive human subjects, as obtained with the
wire12,14,53,55,56,58–68 or pressure51,69–71 myograph method-
ology. In non-diabetic essential hypertensives, all data con-
verge on a pattern of reduced D, increased M/D ratio (M
denoting media width, measured in preference to the
total wall thickness W in all these studies), and constant
media CSA. Not all of these studies have checked vascular
mechanics, but when this was done, the wall stiffness of
hypertensive vessels was either unchanged54,71 or slightly
decreased.51 These aggregated data indicate that small sub-
cutaneous arteries of non-diabetic hypertensives undergo
inward eutrophic remodelling. In contrast, it appears that
diabetes on top of essential hypertension is associated
with media hypertrophy, without a reduction of lumen diam-
eter as measured in passive conditions.65,66 The same hyper-
trophy was also shown by one of these studies66 in
normotensive diabetics, supporting a pressure-independent
effect of diabetes on resistance vessel morphology.23
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Finally, the limited data available suggest that, contrary to
the essential form, hypertension secondary to renovascular
disease could promote media growth in human small subcu-
taneous arteries.53,67,68
There are at least two caveats regarding the interpret-
ation of these clinical data. First, the extent to which
they might be contaminated by the aforementioned
sampling problem is impossible to assess. Second, the sub-
cutaneous vasculature is not necessarily representative of
other vascular beds. There are a few observations to miti-
gate the latter concern. We may recall here the evidence
of eutrophic remodelling in the intestinal microcirculation
of hypertensive patients presented by Short.28 In addition,
a positive correlation has been found in hypertensive
patients between coronary ﬂow reserve and the M/D
ratio of subcutaneous arteries, indeed supporting that
hypertensive changes of microvascular structure were not
limited to the subcutis.72 Finally, Harazny et al.73 have
very recently been able to evaluate the W/D ratio of
retinal arterioles in patients with treated hypertension
and without advanced retinopathy (stages III or IV). To
that effect, they used laser Doppler imaging whereby
outer and inner diameters were respectively determined
from reﬂection and perfusion images. Results indicated a
higher ratio when blood pressure control was poor than
when it was satisfactory.
4. Mechanisms of altered resistance vessel
structure in hypertension
It is thought that hypertensive remodelling of resistance
vessels results from complex, yet incompletely understood
interactions between genetic factors, intrinsic adaptation
of vascular wall to altered mechanical conditions, and neu-
rohumoral as well as local trophic inﬂuences.9
4.1 Genetic factors
Considering the polygenic nature of essential hypertension,
it would be consistent that particular traits would exist
that would favour alterations of vascular structure. Some
evidence along this line is given by comparison of the
same vessels in different strains of genetically hypertensive
animals. Speciﬁcally, medial hypertrophy of large mesen-
teric arteries seems much more marked in mRen-2 trans-
genic rats than in age-matched SHRs.36 Another way to
search for ‘remodelling traits’ is to examine the ontogeny
of microvascular structure in genetic hypertension. Results
have been heterogeneous. A structural reduction of lumen
diameter has been detected in the small mesenteric arteries
of young SHRs, when their blood pressure did not yet differ
from that of age-matched WKY controls74 but normal struc-
ture of these same vessels has been reported in mRen-2
transgenic rats at the prehypertensive stage.39 Regarding
human data, forearm Rmin was higher in young normoten-
sive subjects with than without a family history of essential
hypertension.75,76 In neither study however was it clear that
structural changes antedated hypertension, because blood
pressure, although in the normotensive range, was some-
what higher in the offsprings of hypertensive parents. In a
similar group of subjects, subcutaneous small arteries
failed to demonstrate any structural abnormality when
examined with wire myography (Figure 5).60 The view that
essential hypertension could be initiated by a primary,
genetically determined remodelling of resistance vessels is
now largely abandoned.
4.2 Pressure-dependent factors
Structural narrowing of resistance vessels occurs in all like-
lihood posterior to the onset of essential hypertension,
although possibly prior to left ventricular hypertrophy or
any other end-organ damage.71 Posteriority is furthermore
self-evident in case of secondary hypertension. In addition,
the evidence for a causal pathway leading from high blood
pressure to microvascular remodelling is fairly strong. In
the early 70s, Folkow et al.77 reported that the abnormal
elevation of hindquarter Rmin seen in adult SHR was abol-
ished by prior partial ligation of the abdominal aorta
below the renal arteries carried out at the pre-hypertensive
stage, an intervention that protected the lower limb vessels
from exposure to high blood pressure. Also in pre-
hypertensive SHRs, Bund et al.78 partially ligated the left
external iliac artery, let the animals develop hypertension,
and then observed with wire myography that distal
femoral arteries excised from the right leg (unprotected)
showed hypertrophic remodelling in comparison with those
taken from the left leg (protected). Similar evidence
exists with models of secondary hypertension.40,79
We have previously reviewed the general tendency of
chronic hypertension to produce media growth in larger as
Figure 5 Morphologic characteristics of small subcutaneous arteries in
untreated hypertensive patients vs. normotensive human subjects. Studies
examined vessels isolated from biopsy material, using either the pressure
myograph or the wire myograph. D internal diameter. M/D ratio of media
thickness to internal diameter. CSA, cross-sectional area. C, normotensive
controls. EH, untreated essential hypertension. EH+D, essential hypertension
and diabetes; RVH, renovascular hypertension. NA, data not available from
original publication. Data are the mean values reported in the various
studies (references in square brackets). *P , 0.05, **P , 0.01, ***P ,
0.001 vs. C. +P , 0.05, ++P , 0.01, +++P , 0.001 vs. EH. Notes: a) Means
and P-values recomputed by pooling the two EH groups reported separately
in the original publication. b) Group EH consisted of normotensive offspring
of hypertensive parents. c) The largest study, comprising 59 controls and
159 non-diabetic patients with essential hypertension.
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opposed to inward eutrophic remodelling in smaller resist-
ance vessels. It is believed that this pattern may be
explained by the general mechanisms that regulate wall
stress (s) in blood vessels.1,42,80 By virtue of the Laplace
law, the same acute elevation of transmural pressure pro-
duces a greater increase of s in larger arteries, due to
their smaller W/D ratio in comparison with more distal nar-
rower vessels. Furthermore, the larger vessels have a very
limited, or even no myogenic response, so that their only
way to regulate s in the face of persistent distension is to
increase wall thickness, by way of a growth response. In con-
trast, smaller vessels have vigorous myogenic tone, which
together with a larger M/D ratio allows them to control s
in the short term by mere active variations of lumen size
and wall thickness. If the elevation of transmural pressure
persists, myogenic constriction progressively gives way to
structural rearrangement of wall material around a smaller
lumen, i.e. the pattern of inward eutrophic remodel-
ling.81,82 The aforementioned greater hypertrophy and
lesser eutrophic remodelling of resistance vessels in hyper-
tensive diabetics65,66 may be understood in this context,
because diabetes impairs myogenic tone.66
A ﬁnal remark relates to the differential effects on vascu-
lar biology of pulsatile vs. steady mechanical forces.83 In
rabbit aorta for example, pulsatile variations of transmural
pressure did not trigger the same intracellular signalling
events [interestingly related to activation of kinases associ-
ated with focal adhesion (FA) points, see below] as did a
steady increase of this variable.84 It is now realized that pul-
satile pressure and ﬂow penetrate much deeper into micro-
vascular networks than previously thought,16 and we may
thus speculate that hypertensive resistance vessels may
not be exposed to the same pulsatile stress/strain than are
normotensive ones. Whether this factor contributes to
remodelling could become an active area for future
research.
4.3 Pressure-independent factors
In hypertensive models, the strategy of protecting a speciﬁc
vascular bed from high blood pressure in order to sort out
pressure-mediated from non-pressure mediated mechanisms
of remodelling has in fact yielded some contradictory
results.79,85,86 The most cited evidence for the importance
of pressure-independent factors in hypertensive remodelling
of resistance vessel has been obtained in rats receiving a
low-rate infusion of angiotensin II. In such conditions,
blood pressure remains initially normal, and then slowly
increases over several days, after which media hypertrophy
of small mesenteric arteries is observed. Co-treatment of
these animals with an infusion of hydralazine completely
prevented hypertension, but had no effect on the develop-
ment of vascular hypertrophy.44
In the following, we shall brieﬂy discuss relevant neurohu-
moral as well as local non-mechanical factors. These might
act independent of pressure, interact with pressure-
dependent mechanisms, or constitute essential mediators
thereof, with the current state of knowledge not allowing
to fully distinguishing between these possibilities.
4.4 Sympatho-adrenergic system
Sympathetic activation is a hallmark of human essential
hypertension, and plays a well-known, in part
pressure-independent role in the development of left ventri-
cular hypertrophy. A trophic impact of adrenergic stimu-
lation on vascular smooth muscle has also been
demonstrated in vitro. For example, stimulation of a1 adre-
noreceptors enhanced the production of extracellular
matrix (ECM) and the expression of transforming growth
factor b (TGF-b) by cultures of primary human aortic
smooth muscle cells, while b1 stimulation had the opposite
effects.87 The recent suggestion of a role for dysregulated
production of TGF-b in hypertensive structural narrowing
of resistance vessels must be noted here.88
On the other hand, there are no conclusive data, whether
from animal models or clinical studies, to support an inde-
pendent role of sympathetic activation in the pathogenesis
of hypertensive remodelling of resistance vessels (for
review, see22). In adult SHRs who underwent neonatal sym-
pathectomy plus ablation of the adrenal medulla at 4
weeks, vascular structure was normal, but so was blood
pressure.89 In Sprague-Dawley rats made hypertensive with
a slow low dose infusion of angiotensin II, neonatal sym-
pathectomy+medullectomy inﬂuenced neither the time-
course of blood pressure, nor the development of medial
hypertrophy in small mesenteric arteries.90 In the clinical
arena, the structure of small subcutaneous arteries did not
differ between patients with a hyperactivated
sympatho-adrenergic system due to pheochromocytoma
and patients with essential hypertension.91 b-blockers
have consistently failed to inﬂuence the structure of these
arteries in essential hypertensive patients (see below).
4.5 Angiotensin II
Beyond contraction of smooth muscle, angiotensin II has the
ability to promote many processes in cardiovascular tissue,
including cell growth, migration, differentiation, and apop-
tosis, as well as modulation of ECM composition and turn-
over. For these reasons, angiotensin II is a likely candidate
for a pivotal role in remodelling throughout the cardiovascu-
lar system.92 Interestingly, the growth-promoting properties
of angiotensin II have been demonstrated at physiological
concentrations (10210 M)93 in cultures of primary smooth
muscle cells obtained from human small subcutaneous
arteries.94 In this respect, cells from patients with essential
hypertension were more sensitive than cells from normoten-
sive controls.94 The aforementioned results with slow
low-dose infusion of angiotensin II in the rat have convin-
cingly implicated this peptide as a primary,
pressure-independent mediator of small mesenteric artery
medial hypertrophy in this model.44 It has been speculated
that angiotensin II may participate in inward eutrophic
remodelling by differentially favouring growth on the
luminal side and apoptosis on the abluminal side of vascular
wall.95
4.6 Reactive oxygen species
It is now well accepted that vascular production of reactive
oxygen species (ROS) is abnormally high in hypertension.96
ROS in turn may trigger many cellular events, including
growth. For example, the angiotensin II-induced growth of
rat aortic smooth muscle cells was suppressed either by
treatment with diethyldithiocarbamate, as ROS scavenger,
or by overexpression in these cells of superoxide dismutase,
an antioxydant enzyme.97 On in vitro administration of
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angiotensin II, SMCs isolated from human small subcutaneous
arteries also had a ROS-mediated growth response, which
very interestingly was more marked in cells from hyperten-
sive than from normotensive subjects.98
4.7 Nitric oxide
A low bioavailability of nitric oxide (NO), linked to endo-
thelial dysfunction and possibly mediated in part by excess
ROS, seems widely implicated at multiple levels in the patho-
genesis of hypertension.99 NO has myriads of biological
effects, among which a negative control exerted on cellular
growth. Mice with deletion of the gene coding for the endo-
thelial form of nitric oxide synthase (eNOS) are mildly hyper-
tensive. In these mice, the inward hypotrophic remodelling of
conduit arteries, which normally follows a chronic reduction
in blood ﬂow, is replaced by a hyperplastic response.100
Hypertrophic remodelling of small coronary arteries has
been observed in rats made hypertensive by the chronic
administration of NG-methyl-l-arginine, an inhibitor of NOS,
and this structural abnormality was not reversed when
blood pressure was normalized by concomitant treatment
with hydralazine,45 suggesting that suppression of NO could
enhance vascular growth in a pressure-independent manner.
Interestingly, a simulation carried out with the aforemen-
tioned computational model of rat mesenteric microcircula-
tion by Pries et al.27 suggested that even minor degrees of
endothelial dysfunction can powerfully potentiate the
impact of hypertension on microvascular structure. In hyper-
tensive humans, endothelial dysfunction of the microvascula-
ture has been demonstrated in the skin.101
4.8 The extracellular matrix–integrin–
cytoskeleton axis
Integrins are ubiquitous dimeric transmembrane receptors
which ligate speciﬁc sites of various ECM proteins, for
example ﬁbronectin and collagens.80,102,103 Their cyto-
plasmic part binds cytoskeletal proteins such as actin.
Within the cell membrane, ligated integrin complexes
occur in clusters called FA points. This arrangement allows
for a tight mechanical connexion between ECM and cytoske-
leton. FAs also comprise a complex signalling apparatus,
able to inﬂuence all major cell functions, including cell
cycle, gene expression, substrate adhesion, motility, and
membrane ion channel permeability. In a multicellular
environment, any change in cell number, shape, or position
requires the active participation and dynamic restructuring
of the ECM–integrin–cytoskeleton axis. This axis is the
major mean that cells have to sense their mechanical
environment and react accordingly. For example, it has
been shown that the aVb3 and a5b1 integrins are the
stretch sensors responsible for initiating myogenic contrac-
tion in resistance vessels.104
With this background, it seems logical that the ECM–
integrin–cytoskeleton axis should be profoundly implicated
in hypertensive remodelling of resistance vessels. Rat
mesenteric arteries were pressurized in vitro and exposed
to endothelin-1 for 3 days; eutrophic remodelling ensued
an effect blocked by an antibody directed against the b3
integrin subunit.105 In eutrophically remodelled small
mesenteric arteries of hypertensive mRen-2 transgenic
rats, expression of the aV integrin subunit was increased,
in comparison with similar vessels from normotensive
controls.39 In that study furthermore, some mRen-2 rats
received at the pre-hypertensive stage a peptide antagonist
of aV: this treatment had no effect on the further time
course of blood pressure, but modiﬁed the remodelling of
mesenteric arteries from mainly eutrophic to mainly
hypertrophic.
4.9 Adventitial cells
The vascular adventitia has traditionally been considered as
a passive supportive structure. There is mounting evidence
that it also actively participates in general remodelling pro-
cesses.106 In rat carotid artery subjected to balloon injury,
adventitial ﬁbroblasts differentiated to myoﬁbroblasts and
migrated through the media to participate in the formation
of neointima.107 In rats with hypertension secondary to
chronic pharmacologic inhibition of NOS, the basilar artery
was eutrophically remodelled, and its adventitial layer
revealed a greatly increased cellular density.108 Eutrophi-
cally remodelled mesenteric arteries of SPSHRs also had
abnormally dense adventitial cellularity, and in addition dis-
played a striking number of advential-looking cells in the
media.109 Considering the potential role of sympathetic
activation evoked above, it is relevant that adventitial
ﬁbroblasts highly express a1-adrenergic receptors, and
that noradrenaline can stimulate their proliferation and
differentiation to myoﬁbroblasts, at least in vitro.110
5. Effects of antihypertensive drug treatment
on the structure of resistance arteries
This topic was systematically reviewed by Christensen and
Mulvany111 in 2001. Thirty clinical studies were identiﬁed
where resistance vessel structure was evaluated before
and after blood pressure lowering with antihypertensive
medication. All major classes of drugs were tested, over
periods ranging from 1 to 84 months, in all cases with sub-
stantial improvement of blood pressure control. Twenty-one
studies inferred structure from the measurement of Rmin
with forearm plethysmography and the remaining 9 used
myography of biopsied small subcutaneous arteries. It
came out quite clearly that at least partial reversal of
hypertensive structural changes could be obtained with all
drug classes, except with b-blockers. As shown in Table 1,
more recent studies of biopsied subcutaneous arteries
have mostly borne out this conclusion. Very recently,
Mathiassen et al.112 presented data in 28 patients with
essential hypertension. In these subjects, forearm Rmin
had remained unchanged and abnormally high despite excel-
lent blood pressure control obtained with a b-blocker for
one full year. For the next year, medication was switched
to an AT1 antagonist (eprosartan), a period during which
blood pressure remained stable while Rmin decreased by
16% (P, 0.01).
The blatant inability of b-blockers to affect the structure
of resistance vessels has been attributed to their mode of
action through reduction of cardiac output rather than vaso-
dilation.111,112 Considering our previous discussion on
mechanisms, it is also possible that vasodilator antihyper-
tensive drugs, especially those interfering with the
renin-angiotensin system, inﬂuence vascular structure by
mechanisms independent of haemodynamic factors, but
this issue is completely unsolved at present.
Microvascular remodelling 281
6. Prognostic implication of hypertensive
resistance vessel remodelling
We now have three relevant and concordant clinical
studies. The ﬁrst one was published in 2003 by Rizzoni
et al. Within an 8-year period, 128 patients with either
essential or secondary hypertension had had a gluteal or
omental fat biopsy after being weaned from antihyperten-
sive medication for at least 3 weeks. Follow-up ensued for
a mean duration of 5 years (range 2.6–9.9), with a compo-
site endpoint of various major and minor cardiovascular
events, which occurred in 33 cases. On multivariable analy-
sis, a high M/D ratio of the small artery and a high pulse
pressure were the only independent predictors for event
occurrence. A few years later, the authors extended their
survey as follow-up included more subjects. The expanded
cohort comprised 303 patients observed for a mean dur-
ation of 6.9 years (range 0.6–13.9). It was thus possible
to distinguish major (sudden death, stroke, myocardial
infarction, n = 25) from other cardiovascular events (n =
23). Here, a high M/D ratio was an independent predictor
for the occurrence, not only of any event as before, but
also of any major one.57 Both studies contained a mix of
diabetic and non-diabetic hypertensive patients, which
may be seen as a weak point considering the possible inde-
pendent impact of diabetes on small artery morphology
(see above). However, Mulvany’s group reported essentially
the same results in a more homogeneous cohort of 159 non-
diabetic subjects with essential hypertension (mean follow
up time 10 years, composite outcome of cardiac, cerebro-
vascular, renal, and peripheral arterial events, 30 events in
total).56
In view of these data, should evaluation of small artery
structure become part of clinical evaluation in hypertensive
disease? In the present state of knowledge, probably not, if
only because biopsies of subcutaneous arteries are not prac-
tical on a large scale.113 The aforementioned non-invasive
structural assessment of retinal arterioles73 might seem in
that respect a promising approach, which deserves further
evaluation.113
7. In form of conclusion: Should we aim to
correct resistance vessel structure when
treating hypertension?
At the time of writing the present review, this issue has not
been resolved. The answer could come from two different
types of considerations. First, does remodelling of resistance
vessels participate in hypertensive organ damage? Second,
does this remodelling hamper the proper control of blood
pressure?
The possible involvement of resistance vessel remodelling
in hypertensive end-organ damage has received the greatest
attention in the case of the myocardium.72,114,115 Notably, in
patients with essential hypertension, coronary ﬂow reserve
improved concomitantly with normalization of small subcu-
taneous artery structure following 1 year of treatment
with perindopril, an ACE inhibitor. In contrast, coronary
ﬂow reserve worsened, and small subcutaneous artery struc-
ture remained unchanged in a parallel group in whom the
same level of blood pressure reduction was achieved over
the same period, by the b-blocker atenonol.115 In that
study, interestingly, myocardial blood ﬂow was measured
with position emission tomography, allowing expression of
ﬂow per unit mass of tissue, thus removing at least in part
the inﬂuence of left ventricular hypertrophy (which
regressed with the ACE inhibitor only). Assuming a corre-
lation between the remodelling of subcutaneous and intra-
myocardial resistance arteries, as suggested by another
clinical study,72 correction of this anomaly would contribute
to improve the functional status of the coronary circulation.
That altered vascular structure could hamper the thera-
peutic control of blood pressure would be suggested by an
oversimpliﬁed version of the Folkowian view—i.e. high
blood pressure breeding remodelling which in turn breeds
high blood pressure. However, Folkow9 himself has stressed
that this positive feed-back loop would be unsustainable
without intervention of powerful counter-regulatory mech-
anisms, the nature of which remains incompletely under-
stood. As also underscored by Mulvany,21 the control of
blood pressure involves: (i) one or several setpoints for
Table 1 Effect of antihypertensive treatment on blood pressure and on resistance artery structure
Primary drug Drug type %change MBP %change M/D Treatment duration (months) Reference
Amlodipine CaB 28%** 39%* 12 116
a
Atenolol b+ 211% 7% 12 117
Atenolol b+ 218%*** 0% 12 115
Perindopril ACE 217%*** 215%* 12 115
Losartan ARB 210%** 215%* 12 116
a
Candesartan ARB 27%* 216%** 12 118
Valsartan ARB 213%* 219%* 12 117
Enalapril ACE 213%* 221%** 12 118
Irbesartan ARB 0% 223%** 12 119
b
Recent clinical studies which documented changes in mean blood pressure (MBP) and in media/lumen ratio (M/D) of small subcutaneous arteries following
antihypertensive treatment. Calcium antagonists (CaB), b+ antagonist of beta-adrenergic receptors, ACE inhibitors of the angiotensin-converting enzyme,
ARB antagonist of the AT1 angiotensin receptor.
aOne study reporting the M/D ratio of vessels ,100 mm, measured with histology of skin biopsies.116 In all others, 200–300 mm arteries were mounted in a
wire115,118 or pressure117,119 myograph.
bOne study in which patients whose blood pressure was well controlled with a b-blocker were crossed-over to an ARB.119
*P , 0.05.
**P , 0.01.
***P, 0.001.
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this variable, (ii) fast processes (i.e modulation of vessel
tone through local and neurohumoral mechanisms) to keep
blood pressure closest to this (these) setpoint(s), and (iii)
slow processes (remodelling) which allow adaptation to a
sustained setpoint change, in energetically economical
terms (i.e. reduced lumen diameter at normal activation
level of smooth muscle in resistance vessels). What deter-
mines the setpoint(s) is presently unknown, although the
need to maintain appropriate blood and oxygen supply to
various organs, notably the kidney, is probably involved.21
In the hypertensive circulation, correcting the structure
without also changing the setpoint would only activate neu-
rohumoral and other mechanisms to keep blood pressure
high. Consistent with these considerations, we have noted
above a marked dissociation between the impacts of antihy-
pertensive therapy on blood pressure and on resistance
vessel structure (Table 1).111 If and how the various drug
classes affect the setpoint for blood pressure might
become a focus of future research.
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